Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/GSK Preparing Boniva NDA For Once-Quarterly I.V. Formulation

This article was originally published in The Pink Sheet Daily

Executive Summary

Filing is planned for late 2004/early 2005 based on positive Phase III results. I.V. infusion formulation of ibandronate would be the first injectable bisphosphonate for osteoporosis, administered once every two or three months.

You may also be interested in...



Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up

FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.

Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up

FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.

Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint

A Merck head-to-head trial showing an efficacy advantage for its osteoporosis agent Fosamax versus Actonel is "misleading" because the claim is based on bone mineral density rather than the preferred fracture risk endpoint, competitors maintain

Related Content

Topics

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel